E

Evotec SE
OTC:EVOTF

Watchlist Manager
Evotec SE
OTC:EVOTF
Watchlist
Price: 8.01 USD Market Closed
Market Cap: $1.4B

Operating Margin

-13.2%
Current
Declining
by 7.1%
vs 3-y average of -6.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-13.2%
=
Operating Income
€-99.8m
/
Revenue
€756.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-13.2%
=
Operating Income
$-99.8m
/
Revenue
€756.3m

Peer Comparison

Country Company Market Cap Operating
Margin
DE
Evotec SE
XETRA:EVT
1.1B EUR
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
165.5B USD
Loading...
CH
Lonza Group AG
SIX:LONN
37.6B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
279.2B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR
Loading...

Market Distribution

Lower than 86% of companies in Germany
Percentile
14th
Based on 3 747 companies
14th percentile
-13.2%
Low
-61 459.6% — 0.7%
Typical Range
0.7% — 9.8%
High
9.8% — 94 540%
Distribution Statistics
Germany
Min -61 459.6%
30th Percentile 0.7%
Median 4.5%
70th Percentile 9.8%
Max 94 540%

Evotec SE
Glance View

Nestled within Germany's innovation-focused sector, Evotec SE has carved a niche for itself as a leading player in the field of drug discovery and development solutions. From its inception, Evotec has thrived on its commitment to delivering comprehensive solutions that expedite the journey from conceptualization to clinical success. At the core of its business model is a robust and scalable platform approach, which integrates cutting-edge technologies such as high-throughput screening, phenotypic screening, and computational biology. By leveraging these advanced methodologies, Evotec collaborates with pharmaceutical giants, biotech firms, and academic institutions, offering them customized services and shared-risk alliances. This symbiotic partnership model not only accelerates drug discovery but also minimizes the resource constraints typically associated with early-stage research. Evotec's revenue generation is intricately tied to its partnerships and collaborations, which involve milestone and royalty payments, alongside direct service fees. Its business strategy is propelled by a unique combination of proprietary drug development initiatives and strategic collaborative ventures. This dual-pronged approach allows Evotec to share the financial risk of drug development while maintaining potential upside through successful compounds. Moreover, the company's proactive investments in its own pipeline complement the service-based revenue, as they position Evotec to capture significant gains from future licensing or the eventual commercialization of internally researched drugs. With a strong emphasis on scientific excellence and commercial viability, Evotec meticulously balances innovation with strategic foresight, crafting a sustainable business that stands resilient amid the ever-evolving pharmaceutical landscape.

EVOTF Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-13.2%
=
Operating Income
€-99.8m
/
Revenue
€756.3m
What is Evotec SE's current Operating Margin?

The current Operating Margin for Evotec SE is -13.2%, which is below its 3-year median of -6.1%.

How has Operating Margin changed over time?

Over the last 3 years, Evotec SE’s Operating Margin has decreased from -0.3% to -13.2%. During this period, it reached a low of -13.2% on Sep 30, 2025 and a high of 4.8% on Mar 31, 2023.

Back to Top